These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efficacy of sarolaner on the treatment of myiasis caused by Cochliomyia hominivorax (Diptera: Calliphoridae) in dogs.
    Author: Oliveira PC, Almeida GPS, Cardoso JD, Tavares RB, Fernandes JI, Correia TR, Verocai GG, Scott FB.
    Journal: Vet Parasitol; 2019 Dec; 276():108966. PubMed ID: 31759192.
    Abstract:
    The aim of this study was to evaluate the larval expulsion, larvicidal effect, retention rate of dead larvae and overall efficacy of sarolaner on the treatment of myiasis caused by New World screwworm Cochliomyia hominivorax in naturally infested dogs. Eight Beagle dogs received a single dose of saroalner 40 mg, with dosage ranging from 2.7 mg/kg to 3.7 mg/kg. Evaluations occurred every 15 min in the first hour, every hour for up to 6 h, and after 24 h of treatment. At 24 h post-treatment, total wound cleaning was performed, including removal and counting of remaining live and dead larvae. The animals received antibiotic, analgesic and wound cleaning support until complete wound healing. The average expulsion of the larvae was 50.9 % occurring mainly after 4 h of treatment. The larvicidal effect was 70.6 % at 6 h after treatment and 100 % at 24 h. The mean retention rate of dead larvae of sarolaner was 33.9 %, The overall efficacy was 100 %, thus making sarolaner an excellent treatment option in myiasis caused by C. hominivorax larvae in dogs.
    [Abstract] [Full Text] [Related] [New Search]